ADVANZ PHARMA’s Post

We are excited to share that our Founder and CEO, Francisco Leon, will be speaking at the Sino-American Pharmaceutical Professionals Association (SAPA) Annual Meeting. The event’s theme, “Redefining Medicine: Navigating Resilience, Transforming Lives,” aligns with Tolerance Bio’s mission to develop transformative medicines that restore immune balance and address the root cause of autoimmune diseases. Francisco will be sharing insights from his extensive experience in drug repositioning, including examples from his work at Celimmune, Provention Bio, and our current innovations at Tolerance Bio. For more details, visit the SAPA Annual Meeting website: https://lnkd.in/eJv-JwN6 #SAPA2024 #SAPA #SAPAAC  #biotech #drugdevelopment #healthcareinnovation

IPD Analytics has released its Biosimilar Pipeline Report for 1H 2025, which provides an outlook for potential approvals and launches across the biosimilar landscape over the 2025–2028 horizon. In addition, the report examines trends in average sales prices (ASPs) of reference medical-benefit products and provides the full list of biosimilars approved in 2024 to date. Read the report now: https://lnkd.in/e7hzmvTZ Subscribers of IPD can use this report as a companion to our online Clinical Development Tracker within our Payer & Provider Insights platform, which provides up-to-date clinical pipeline information on thousands of products across various disease classes and therapeutic areas. #biosimilars #clinicaldevelopment #drugpricing #stelara #janssen #xolair #novartis #prolia #amgen #ocrevus #genentech #eylea #regeneron

IPD Analytics has released its Biosimilar Pipeline Report for 1H 2025, which provides an outlook for potential approvals and launches across the biosimilar landscape over the 2025–2028 horizon. In addition, the report examines trends in average sales prices (ASPs) of reference medical-benefit products and provides the full list of biosimilars approved in 2024 to date. Read the report now: https://lnkd.in/e7hzmvTZ Subscribers of IPD can use this report as a companion to our online Clinical Development Tracker within our Payer & Provider Insights platform, which provides up-to-date clinical pipeline information on thousands of products across various disease classes and therapeutic areas. #biosimilars #clinicaldevelopment #drugpricing #stelara #janssen #xolair #novartis #prolia #amgen #ocrevus #genentech #eylea #regeneron

𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐢𝐧𝐠 𝐎𝐮𝐫 𝐋𝐚𝐭𝐞𝐬𝐭 𝐑𝐞𝐬𝐩𝐢𝐫𝐚𝐭𝐨𝐫𝐲 𝐍𝐞𝐰𝐬𝐥𝐞𝐭𝐭𝐞𝐫 We are thrilled to announce the release of our latest newsletter, covering business-critical events in the respiratory portfolio. This edition focuses on key areas such as 𝐀𝐬𝐭𝐡𝐦𝐚, 𝐂𝐎𝐏𝐃, 𝐂𝐡𝐫𝐨𝐧𝐢𝐜 𝐂𝐨𝐮𝐠𝐡, 𝐏𝐮𝐥𝐦𝐨𝐧𝐚𝐫𝐲 𝐇𝐲𝐩𝐞𝐫𝐭𝐞𝐧𝐬𝐢𝐨𝐧, 𝐈𝐝𝐢𝐨𝐩𝐚𝐭𝐡𝐢𝐜 𝐏𝐮𝐥𝐦𝐨𝐧𝐚𝐫𝐲 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬, 𝐚𝐧𝐝 𝐂𝐲𝐬𝐭𝐢𝐜 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬.   For a quick overview, check out the Executive Summary, which highlights the most important updates at a glance. This edition has recent updates from companies, including AstraZeneca, Vertex Pharmaceuticals, ALIVEGEN USA, INC., Windward Bio, tiakis Biotech AG, MediaRadar, Inc. and Lupin.   Dive deeper into the respiratory and pulmonary landscape with in-depth coverage, including: ✅ Market landscape analysis ✅ Company competitive analysis ✅ Strategy and market opportunities ✅ Key upcoming milestones   Looking for tailored insights or support for your strategic initiatives? Reach out to us at info@adametnext.com. 𝐏𝐫𝐞𝐩𝐚𝐫𝐞𝐝 𝐛𝐲: Ziya Pailwan, Mritunjay Singh Chandel Virendra Kumar AdametNext #RespiratoryPortfolio #MarketInsights #Respiratory #Competitiveintelligence #Strategyandinsights United Therapeutics Corporation, VICORE HEALTH LTD, Krystal Biotech, Inc. and Protalix Biotherapeutics.